Tera Software-ITI consortium wins Rs 1901 crore BharatNet Phase-3 project in Northeast
The total value of the awarded contract is ₹1,901.10 crore (Rupees One Thousand Nine Hundred One Crore Ten Lakh Fifty-One Thousand Five Hundred Seven and Sixty-Four Paisa). The project includes the design, supply, construction, installation, upgradation, operation, and maintenance of the Middle Mile Network infrastructure.
This contract falls under BharatNet Phase-3, which is aimed at the creation, upgradation, and O&M (Operation and Maintenance) of a Middle Mile Network using the Design-Build-Operate-Maintain (DBOM) model. The objective of BharatNet Phase-3 is to enable broadband connectivity to 2,50,000 Gram Panchayats across India, as part of the Digital Bharat Nidhi initiative.
With this award, the total value of orders received by the Tera Software and ITI Limited consortium from Bharat Sanchar Nigam Limited (BSNL) has reached ₹7,005 crore.
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
13 minutes ago
- Business Upturn
V2 Retail Q1 FY26 business update: Company reports 51% YoY revenue growth, adds 28 new stores
V2 Retail Limited has reported a strong start to FY26, delivering impressive growth in its Q1 business update. The company's standalone revenue surged to ₹628 crore in Q1 FY26, marking a 51% year-on-year jump from ₹415 crore in Q1 FY25. This performance highlights the success of its product-first approach, robust sell-through rates, and deeper market reach. Same-store sales growth (SSSG) normalized at 10%, despite an early Eid impact in April. May and June recorded strong double-digit growth, reflecting steady consumer demand and smart assortment planning. Sales per square foot for Q1 stood at ₹957, showing solid store-level productivity—even with a higher contribution from new stores. This was made possible through improved merchandising, faster stock replenishments, and strict inventory control. V2 Retail also expanded its footprint by opening 28 new stores during the quarter while closing one underperforming outlet. The total store count now stands at 216, covering a retail area of 23.48 lakh sq. ft. The company continues to focus on Tier 2 and Tier 3 cities, strengthening its mission to bring affordable fashion to emerging India. The company emphasized its strong momentum going into FY26, driven by innovation, data-backed merchandising, and customer trust. With an expanding footprint and a clear focus on value fashion, V2 Retail is well-positioned to lead in India's fast-evolving retail landscape. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
13 minutes ago
- Business Upturn
Aurobindo Pharma's subsidiary CuraTeQ Biologics secures marketing approval for trastuzumab biosimilar ‘Dazublys'
Aurobindo Pharma's wholly owned step-down subsidiary, CuraTeQ Biologics s.r.o., has achieved a major milestone with the European Commission granting marketing authorization for Dazublys™, its trastuzumab biosimilar. This approval follows the positive opinion issued by the European Medicines Agency's (EMA) CHMP in April 2025, recommending the product for authorization. Dazublys™ is a biosimilar of trastuzumab, a widely used monoclonal antibody in the treatment of HER2-positive breast and gastric cancers. With this latest approval, Dazublys™ becomes CuraTeQ's third EMA-approved biosimilar, following Dyrupeg™ (approved in April 2025) and Zefylti™ (approved in February 2025). It also marks the fourth biosimilar approval for CuraTeQ in the European region, including Bevqolva™, which received a green light from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in December 2024. This continued string of regulatory successes further strengthens Aurobindo Pharma's global biosimilar portfolio and underscores the company's commitment to expanding access to high-quality, affordable biologics in key regulated markets. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
CNBC
an hour ago
- CNBC
How AI-generated influencers are taking over YouTube
Virtual YouTubers like Bloo promised a new era of entertainment, combining human creativity with AI scalability. But their rapid rise is raising concerns about authenticity and audience trust. Tools like Character-3 make creating these virtual stars faster than ever, blurring the line between real and synthetic. CNBC explores what this means for the future of creators and the business behind them.
